Clinical trial · Interventional
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Trastuzumab (Herceptin) With Docetaxel (Taxotere), Carboplatin and Trastuzumab (Herceptin) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification
NCT00047255CI-TRIAL-00046342completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if docetaxel and trastuzumab are more effective with or without carboplatin in treating women who have HER2-positive breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of combining docetaxel and trastuzumab with or without carboplatin in treating women who have HER2-positive stage IIIB or stage IV breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin | Drug | Carboplatin | ALIAS |
| docetaxel | Drug | Docetaxel | ALIAS |
| trastuxumab | Biological | — | UNRESOLVED |
| trastuzumab | Biological | Trastuzumab | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Herceptin plus docetaxel
- description
- Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes. Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes. Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes.
- interventionNames
- Drug: docetaxel
- Biological: trastuxumab
- type
- EXPERIMENTAL
- label
- Docetaxel, Carboplatin, and Herceptin
- description
- Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins. Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins. Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed adenocarcinoma of the breast
* Stage IIIB, IIIC, or IV
* HER2-positive
* Measurable or evaluable disease
* Patients with osteolytic bone lesions as only site of disease must have at least 2 lytic sites confirmed by bone x-ray, MRI, or CT scan
* None of the following are eligible as only manifestation of metastatic disease:
* Blastic bone metastases
* Mixed bone metastases
* Lymphangitic carcinomatosis
* Ascites
* Pleural/pericardial effusion
* Lymphangitis cutis/pulmonis
* Inflammatory breast disease
* Abdominal masses not confirmed and followed by imaging techniques
* Cystic lesions
* No prior or known concurrent clinical manifestation of brain or leptomeningeal involvement
* Hormone receptor status:
* Not specified
PATIENT CHARACTERISTICS:
Age
* 18 to 75
Sex
* Female
Menopausal status
* Pre- or post-menopausal
Performance status
* Karnofsky 60-100%
Life expectancy
* Not specified
Hematopoietic
* Neutrophil count at least 2,000/mm3
* Platelet count at least 100,000/mm3
* Hemoglobin at least 10 g/dL
Hepatic
* Bilirubin no greater than upper limit of normal (ULN)
* AST and ALT no greater than 5 times ULN
* Alkaline phosphatase no greater than 5 times ULN (unless due to bone metastases or any nonmalignant bone disease and in absence of liver disorders)
* AST and/or ALT greater than 1.5 times ULN AND alkaline phosphatase greater than 2.5 times ULN ineligible
Renal
* Creatinine no greater than 2 mg/dL
* Creatinine clearance at least 60 mL/min
Cardiovascular
* LVEF normal by MUGA or echocardiogram
* No myocardial infarction within the past year
* No unstable angina pectoris
* No documentation of congestive heart failure
* No concurrent grade 3 or 4 cardiovascular arrhythmia
* No poorly controlled hypertension (i.e., diastolic pressure greater than 100 mmHg)
Pulmonary
* No severe dyspnea due to complications of advanced malignancy
* No respiratory insufficiency requiring supplemental oxygen
Other
* No significant neurologic or psychiatric disorders (e.g., psychotic disorders, dementia, or seizures) that would preclude study
* No pre-existing sensory or motor neuropathy grade 2 or greater
* No other serious illness or medical condition
* No active uncontrolled infection
* No active peptic ulcer disease
* No unstable diabetes mellitus
* No other prior or concurrent malignancy except for:
* Curatively treated nonmelanoma skin cancer
* Carcinoma in situ of the cervix
* Other curatively treated cancer and disease free for at least 10 years
* No known allergic reactions to study drugs
* No contraindications for the use of corticosteroids
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
* See Chemotherapy
* No prior trastuzumab (Herceptin) for locally advanced or metastatic disease
* Prior trastuzumab-containing regimen (except with taxane) as adjuvant or neoadjuvant therapy allowed provided relapse occurred at least 6 months after therapy
Chemotherapy
* No prior chemotherapy for locally advanced or metastatic disease or local recurrence
* No prior chemotherapy with anthracycline or anthracenedione regimens with cumulative doses of more than 360 mg/m2 of doxorubicin, 720 mg/m2 of epirubicin, or 72 mg/m2 of mitoxantrone
* No prior platinum-containing regimen as adjuvant or neoadjuvant chemotherapy
* At least 4 weeks since prior anthracyclines or anthracenediones
* Prior taxanes as adjuvant or neoadjuvant chemotherapy allowed provided relapse occurred at least 6 months after therapy
* Prior taxane with trastuzumab as adjuvant or neoadjuvant chemotherapy allowed provided relapse occurred at least 12 months after therapy
* No concurrent amifostine
Endocrine therapy
* Prior hormonal therapy in the adjuvant or metastatic setting allowed provided patient has progressive disease and therapy has stopped before study entry
* Concurrent chronic corticosteroids allowed if initiated more than 6 months before study entry and at a low dose (no greater than 20 mg methylprednisolone or equivalent)
* No concurrent raloxifene, tamoxifen, or other selective estrogen receptor modulators
* No concurrent hormonal therapy
Radiotherapy
* No prior radiotherapy to study lesion unless clear progression
* At least 4 weeks since prior radiotherapy (unless radiotherapy involved only a single field to treat a single metastatic bone lesion)
* Concurrent radiotherapy for palliative treatment allowed
Surgery
* Not specified
Other
* Recovered from prior antitumor therapy
* At least 30 days since prior experimental drugs
* No other concurrent experimental drugs
* No other concurrent anticancer therapy
* No concurrent bisphosphonates if osteolytic bone metastases are only site of disease
* If receiving concurrent bisphosphonates other than for bone metastases only, must have been started at least 3 months before study entry
* No concurrent primary prophylactic antibiotics
* No concurrent cardioprotectors (e.g., dexrazoxane)References
Publications (4)
- BACKGROUNDPress MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y, Sullivan-Halley J, Santiago A, Park JM, Riva A, Slamon DJ. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005 Sep 15;11(18):6598-607. doi: 10.1158/1078-0432.CCR-05-0636. PMID 16166438
- RESULTPegram M, Forbes J, Pienkowski T, et al.: BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). [Abstract] J Clin Oncol 25 (Suppl 18): A-LBA1008, 2007.
- RESULTValero V, Roche H, Pienkowski T, et al.: BCIRG 007: serum HER2 levels in women with metastatic HER2-amplified breast cancer. [Abstract] J Clin Oncol 25 (18 Suppl 20): A-1020, 2007.
- RESULTForbes JF, Kennedy J, Pienkowski T, et al.: BCIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC): main time to progression (TTP) analysis. [Abstract] J Clin Oncol 24 (Suppl 18): A-LBA516, 7s, 2006.